LTZ Therapeutics Funding Round

5/6/2026

Venture Equity

$38,000,000

Undisclosed

Proceeds from this round will be used to accelerate development of LTZ's pipeline, supporting the company's ongoing Phase 1 clinical study of its lead asset, LTZ-301, which is actively enrolling patients from multiple top clinical sites in the US, as well as the Investigational New Drug (IND) filing and Phase 1 initiation of its second asset, LTZ-232.

Private & Independent

Biopharmaceutical

1100 Island Dr. 103
Redwood City, 94065
USA

Undisclosed

LTZ Therapeutics is an immunotherapy-focused biotech company pursuing the development of novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need. LTZ is focused on leveraging the power of innate immunity (e.g., macrophages) and elimination of immunosuppression (e.g., T regulatory cells, cancer-associated fibroblasts) as these areas have been shown to offer tremendous potential for developing innovative and effective therapies. Specifically, LTZ is developing its own novel innate engager platform to effectively activate macrophages in addition to natural killing (NK) cells as effectors to deliver direct anti-tumor and anti-immunosuppressive cell killing and promote inflammation in the tumor microenvironment -- indirectly resulting in activated adaptive immunity and long-term memory.